MAP2K7 and melanoma: Although sequential therapy, that is, treatment with a BRAF inhibitor followed by BRAF/MEK dual inhibition is not recommended in the management of BRAF-mutant melanoma, we decided to add the MEK inhibitor cobimetinib to vemurafenib.